← Back to Screener
Tectonic Therapeutic, Inc. Common Stock (TECX)
Price$28.76
Favorite Metrics
Price vs S&P 500 (26W)75.46%
Price vs S&P 500 (4W)-10.73%
Market Capitalization$554.10M
All Metrics
Book Value / Share (Quarterly)$13.41
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.22
Price vs S&P 500 (YTD)37.33%
EPS (TTM)$-4.04
10-Day Avg Trading Volume0.18M
EPS Excl Extra (TTM)$-4.04
EPS (Annual)$-4.05
ROI (Annual)-29.46%
Cash / Share (Quarterly)$13.54
ROA (Last FY)-28.41%
EBITD / Share (TTM)$-4.54
Cash Flow / Share (Annual)$-3.22
P/B Ratio2.20x
P/B Ratio (Quarterly)1.55x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-9.38x
ROA (TTM)-25.83%
EPS Incl Extra (Annual)$-4.05
Current Ratio (Annual)26.63x
Quick Ratio (Quarterly)26.32x
3-Month Avg Trading Volume0.34M
52-Week Price Return68.05%
Revenue / Employee (TTM)$0
52-Week High$36.03
EPS Excl Extra (Annual)$-4.05
26-Week Price Return84.21%
Quick Ratio (Annual)26.32x
13-Week Price Return50.03%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)26.63x
Enterprise Value$300.687
Revenue / Employee (Annual)$0
Cash / Share (Annual)$13.54
3-Month Return Std Dev88.28%
Net Income / Employee (TTM)$-1
ROE (Last FY)-29.50%
EPS Basic Excl Extra (Annual)$-4.05
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.04
ROI (TTM)-26.82%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)32.96%
Year-to-Date Return41.47%
5-Day Price Return-1.50%
EPS Normalized (Annual)$-4.05
ROA (5Y Avg)-54.07%
Month-to-Date Return-4.53%
EBITD / Share (Annual)$-4.54
LT Debt / Equity (Annual)0.44x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-4.04
P/B Ratio (Annual)1.55x
Book Value / Share (Annual)$13.41
Price vs S&P 500 (13W)47.16%
Beta1.33x
Revenue / Share (TTM)$0.00
ROE (TTM)-26.87%
52-Week Low$14.39
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.20
4.20
4.20
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TECXTectonic Therapeutic, Inc. Common Stock | — | — | — | — | $28.76 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Tectonic Therapeutics is a biotechnology company discovering and developing therapeutic proteins and antibodies that modulate GPCR function. Using its proprietary GEODe platform, the company designs biologic medicines to treat serious diseases with limited or no existing therapeutic options. The pipeline includes TX2100, a GPCR antagonist for hereditary hemorrhagic telangiectasia and fibrosis, and a program for pulmonary hypertension.